587 Background: Patient survival is impacted by several factors, one of which is stage at diagnosis. From 1976 to 2014, CRC death rate in the United States (US) declined by 51%. This retrospective study was conducted using US Surveillance, Epidemiology and End Results (SEER) data to evaluate 1- and 5-year relative survival for patients with CRC by American Joint Committee on Cancer (AJCC) stage, age and sex at diagnosis. Methods: The study included adults (age ≥20 years) in the SEER-18 registry diagnosed with CRC in 2004-2014. One- and 5-year relative survival rates were stratified by AJCC stage, age group (20-64 vs. ≥65 years) and sex. Results: One- and 5-year survival was calculated by age and stage at diagnosis (Table), and by sex (data not shown). Overall, 5-year survival rates declined compared to 1-year rates, with the biggest decline observed in stage IV patients. Survival was higher in the younger cohort than in patients ≥65 years of age regardless of stage. Both men and women diagnosed with stage IIB CRC had lower 1- and 5-year survival compared to stage IIIA and IIIB groups, consistent with previous findings. Patients with stage IV had the lowest survival irrespective of age or sex. Conclusions: Overall trends in 1- and 5-year relative survival for CRC varied by AJCC stage, age and sex. Since survival is lowest among CRC patients diagnosed at stage IV, particularly in elderly patients, it reinforces the need for early diagnosis and availability of innovative late stage therapies in this population. [Table: see text]

Zika virus and dengue virus serotype 2 were isolated from a patient with travel to Haiti who developed fever, rash, arthralgias, and conjunctivitis. The infecting Zika virus was related to Venezuelan and Brazilian strains but evolved along a lineage originating from strains isolated in 2014 in the same region of Haiti.

Objectives To examine the association between multi-morbid chronic disease and frequency of past six months emergency department (ED) visits, by gender, in a community sample of adults from North Florida (N=7,143). Methods Using logistic regression, we estimated associations between multi-morbid chronic disease and frequent ED use, using gender as an effect modifier. Results Multi-morbid chronic disease was associated with frequent ED use overall, with a stronger association among males. Of the 7,143 respondents, 14.4% were frequent ED users, 58.0% were female, and 61.5% were Black Non-Hispanic. Major findings included that females with 3+ chronic diseases were 2.49 (95% CI= 1.7, 3.6) times as likely as females without chronic diseases to report frequent ED use, compared to males with 3+ chronic diseases, who were 4.98 (95% CI= 2.9, 8.6) times as likely as males without chronic disease to report frequent ED use. Conclusions Multi-morbid chronic disease is very strongly associated with frequent ED use among all, but the association is especially strong among males. Future research is needed to further understand this association and its implication for health care.

Background Non-medical use (NMU) of prescription opioids in youth is of concern since they may continue this pattern into adulthood and become addicted or divert medications to others. Research into risk factors for NMU can help target interventions to prevent non-medical use of opioids in youth. Method The National Monitoring of Adolescent Prescription Stimulants Study (N-MAPSS) was conducted from 2008 to 2011. Participants 10-18 years of age were recruited from entertainment venues in urban, rural and suburban areas of 10 US cities. Participants completed a survey including questions on their use of prescription opioids. NMU was defined as a non-labeled route of administration or using someone else’s prescription. Information on age, gender, alcohol, marijuana and tobacco use was also collected. Summary descriptive and chi-square statistics were calculated using SAS 9.4. Results Of the 10,965 youth who provided information about past 30 day prescription opioid use, prevalence of reported opioid use was 4.8% with 3.2% reported as NMU (n=345) and 1.6% as medical use (MU) only (n=180). More males than females (55.7% vs 44.4%) reported opioid NMU (p<0.0001). Logistic regression revealed that among males (comparing NMU to MU only), current smokers were 4.4 times more likely to report opioid NMU than non-smokers (95% CI: 1.8, 10.7). Among females (comparing NMU to MU only), current smokers and alcohol users were more likely to report opioid NMU than those who had never smoked or used alcohol (OR=3.2, 95% CI:1.4, 7.0 and OR=4.1, 95% CI: 1.7, 10.4, respectively). Conclusions These results suggest that further research on gender differences in opioid NMU is needed; interventions for opioid NMU may need to be gender specific to obtain the best results.